Pancreatic ductal adenocarcinoma (PDAC)
Conditions
Interventions
(Prognostic study) high CTCs group and low CTCs group:NA
(Neoadjuvant efficacy evaluation study) According to the degree of decrease in CTCs values:NA
(Diagnostic test) PC group and Non-PC group:NA
Sponsors
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Prognostic study) 1. Patients with the resectable/borderline resectable PDAC characteristics as defined by the NCCN guidelines and intend to undergo radical surgery; 2. Patients signing informed consent and agreeing to the detection of CTCs from peripheral blood before surgery; 3. 18 years <= age <=80 years; Neoadjuvant efficacy evaluation study 1. Patients with resectable/borderline resectable PDAC characteristics as defined by the NCCN guidelines and proposed neoadjuvant combined surgical treatment after discussion by the Multidisciplinary Team of Pancreatic Diseases; 2. Patients signing informed consent and agreeing to the detection of CTCs from peripheral blood before/after neoadjuvant treatment and after surgery; 3. 18 years <= age <=80 years. Diagnostic test 1. Those who are initially suspected of PC and agree to undergo surgery or EUS-FNA for a clear pathological diagnosis; 2. Patients signing informed consent and agreeing to the detection of CTCs from peripheral blood before treatment; 3. 18 years <= age <=80 years.
Exclusion criteria
Exclusion criteria: 1. Patients with malignant tumors at other sites; 2. Patients with a history of other malignancies within the past 5 years, except cured cervical carcinoma in situ, cured skin basal cell carcinoma, and superficial bladder cancer [Ta, Tis & T1]; 3. Patients who had received any antitumor therapy before enrollment; 4. Patients with long-term oral folic acid; 5. Patients with abnormal white blood cell index before blood collection (white blood cell value greater than 12×10^9/L or less than 2×10^9/L). 6. Those who were in a pregnant state at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS),;Disease-free survival (DFS);sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactCheng Hao
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Outcome results
None listed